Greenwich LifeSciences, Inc.
Close on Oct 19, 2026
- Market cap
- $222.39M
- P/E (TTM)
- –
- Dividend yield
- –
About Greenwich LifeSciences
Pharmaceutical Preparations, SIC 2834
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate is GLSI-100, which combines the GP2 peptide—a 9 amino acid transmembrane peptide of the HER2/neu protein—with the immunoadjuvant GM-CSF to elicit targeted immune responses and prevent breast cancer recurrences. The company evaluates this treatment specifically in HER2/neu-positive breast cancer patients who have residual disease or high-risk features following surgical resection and trastuzumab-based therapies.
The company conducts its clinical operations across multiple regions and is expanding its pivotal Phase III Flamingo-01 clinical trial into Europe, with intentions to activate up to 150 clinical sites worldwide. Greenwich LifeSciences maintains its principal executive offices and headquarters in Stafford, Texas.
Summary of the business section of Greenwich LifeSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Greenwich LifeSciences, Inc.
- Headquarters
- Stafford, TX
- Address
- 3992 Bluebonnet Dr, Building 14 77477
- Phone
- (203) 434-3290
- Website
- greenwichlifesciences.com
- Employees
- 4, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- GLSI
- Exchange
- Nasdaq
- IPO date
- Sep 28, 2020
- Shares outstanding
- 15M, Jul 24, 2026
- Public float
- $56.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1799788
- CUSIP
- 396879108
- ISIN
- US3968791083
- EIN
- 20-5473709
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Snehal Patel | CEO and CFO, Director | 8,324,288 |
| Frank Joseph Daugherty | Chief Medical Officer, Director | 90,121 |
| Jaye Thompson | VP Clinical Reg Affairs | 264,148 |
| David McWilliams | Director | 620,301 |
| Kenneth Hallock | Director | 794,308 |
| Eric Rothe | Director | 313,226 |
Employees
Headcount reported in annual reports
“of May 26, 2026 we had 4 full-time employees and 9 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 31, 2026 | Late filing | Notification of late filing |
| Jul 24, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 15, 2025 | Late filing | Notification of late filing |
| Mar 31, 2025 | Late filing | Notification of late filing |
| May 15, 2024 | Late filing | Notification of late filing |
| Apr 1, 2024 | Late filing | Notification of late filing |
| Feb 20, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 14, 2023 | Late filing | Notification of late filing |
| May 15, 2023 | Late filing | Notification of late filing |
| May 17, 2022 | Late filing | Notification of late filing |
| May 17, 2021 | Late filing | Notification of late filing |
| Sep 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 23, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |